Printer Friendly

Expression and function of PPARs in placenta.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are a family of ligand activated transcription factors belonging to the nuclear hormone receptor superfamily, which mainly regulate the expression of target genes involved in lipid and energy metabolism [1-3]. Three PPAR isotypes have been identified in mammals termed PPAR[alpha], PPAR[delta]/[delta], and PPAR[gamma] [4, 5]. Each isotype is a product of a separate gene, and each one has a distinct tissue distribution relating to the distinct functions. The PPARs play key roles in the metabolic syndrome and overall health of organisms including regeneration of tissues, differentiation, lipid metabolism, and immune response [6]. From a nutritional viewpoint, the PPARs are of importance because of their ability to be activated by long chain fatty acids and their metabolites [7]. Therefore, the PPARs are recognized as candidates in order to improve metabolism and health through suitable diet. In addition, several evidences show the important role of PPARs in reproductive organs [8, 9]. PPAR[gamma] expression has been found in the granulosa, theca, and luteal cells [10]. The PPAR[gamma] may regulate the differentiation and proliferation of the ovarian cells, steroidogenesis, angiogenesis, and prostaglandin production [11], indicating that PPARs modulate the estrous cycle and pregnancy. Retinoic X receptor (RXR) is a functional partner of PPAR. RXR[alpha] and PPAR[gamma] function potently in metabolic diseases and are both important targets for antidiabetic drugs. Coactivation of RXR[alpha] and PPAR[gamma] is believed to synergize their effects on glucose and lipid metabolism [12]. The RXR[alpha] and PPAR[gamma] are essential for mouse placentogenesis [13, 14]. PPAR[gamma] is important for mouse placenta morphology [15]. In addition, PPARs have also been implicated in several aspects of early pregnancy development including implantation, placentation, and trophoblast differentiation [16-18]. Furthermore, PPAR[gamma] and RXR[alpha] are essential for cytotrophoblast cell fusion into a syncytiotrophoblast, which is obligatory for placentation, and these expressions are deregulated in pathological placenta [19]. So, the PPARs maybe a link between energy metabolism and reproduction, which is frequently associated with insulin resistance. This paper will focus on the evidences of PPARs functions in placenta. We will also highlight the effects of co-modulators such as RXRs with PPARs in the experimental models.

2. Expression and Characteristics of PPAR

PPARs ([alpha], [beta], and [gamma]) are nuclear hormone receptors that are known to regulate gene transcription and protein expression levels of fatty acid transport and metabolism mediating proteins through the formation of a DNA binding heterodimer complex [2-4]. All distinct PPAR subtypes share a high degree of structural homology with other members of the superfamily, particularly in the DNA-binding domain and ligand-binding domain (Figure 1). PPARs exhibit wideranging and isotype-specific tissue expression pattern [3-5]. PPAR[alpha] is expressed at high levels in tissues that catabolize fatty acids [20], as in the adult liver, heart, kidney, large intestine, and skeletal muscle. PPAR[delta]/[delta] mRNA is ubiquitously distributed with a higher expression in the digestive tract and the placenta [21]. PPAR[gamma] is mostly expressed in the adipose tissue [22] and immune system. The three isotypes are expressed as early as week 7 of gestation in endodermal and mesodermal origin cells [23]. There are limiting data describing the PPARs expression in endometrial tissue of animal species through the estrous cycle. PPAR[alpha] and PPAR[beta] transcript levels show similar profiles during the estrous cycle [23-26]. PPAR[gamma] mRNA level is quite stable during entire estrous cycle [24-26]. However, the precise role of PPARs in the uterus is not well known, although PPAR[alpha], PPAR[beta], or PPAR[gamma] expressions have been known in uterus of various species. High levels during the luteal phase and low during the follicular suggest the association with steroids function.

A wide variety of compounds have been identified as PPARs ligands. Among the synthetic ligands, fibrates and thiazolidinediones are PPAR[alpha] and PPAR[gamma] agonists, respectively [27]. PPAR[gamma] is also activated by prostaglandins and leukotrienes. In the presence of ligands, conformational changes of the ligand binding domain result in the recruitment of coactivator proteins, release of corepressor proteins, and subsequent assembly of a protein complex that enhances transcription of the target genes [28, 29]. A PPAR[alpha] specific ligand (8S-HETE), a PPAR[gamma] ligand (15-deoxy-delta12, 14-prostaglandin J2), and a peroxisome proliferator (clofibrate) are all able to induce expression of both PPAR[alpha] and PPAR[gamma] [30-32]. Subsequent work has led to the identification of various PPAR ligands that include eicosanoids, hypolipidemic agents, and antidiabetic drugs [33, 34].

Ligand activated PPARs bind as heterodimers with the RXRs on PPAR response elements. A number of PPAR target genes have been characterized to date. Most of these genes are known to have roles in lipid and glucose metabolism [35]. The endometrium is a possible place where PPARs may regulate cyclooxygenase-(COX-) 2 which catalyzes prostaglandin production [36]. They are critical to sustain the function of corpus luteum during the estrous cycle. The PPAR response element has been found upstream of the COX-2 transcriptional site. So, the activation of PPARs affects COX-2 expression in the epithelial cells. In COX-2 deficient mice, failures during the implantation and decidualization may be restored by administration of PPAR[beta] agonists [37], suggesting common pathways of these molecules. Moreover, studies suggest that PPARs participate in uterine functions such as steroidogenesis, cytokine production, and angiogenesis during the estrous cycle and/or pregnancy [38, 39]. Interestingly, PPARs also downregulate nitric oxide synthase (NOS) in human cardiac myocytes and in human prostate cells [40]. As PPARs are expressed as cytotrophoblasts and syncytiotrophoblasts in the placenta, the activation of PPARs may stimulate the production and secretion of hormones such as gonadotropin required during pregnancy and fetal development [41, 42]. Thus, PPARs is essential for the maturation of a functional placenta.

3. Interaction with Retinoid X Receptor for Transactivation

PPARs bind to a variety of PPAR response elements (PPREs) present in the promoter regions of the responsive genes. The transcriptional regulation by PPARs requires heterodimerization with the retinoid X receptor (RXR) (Figure 2). Retinoic acid affects a broad spectrum of physiological processes, including cell growth, differentiation, morphogenesis, reproduction, and development [43], through the action of two types of receptors, the retinoic acid receptors (RARs) and the retinoid-X-receptors (RXRs). When activated by a ligand, the heterodimer modulates transcription activity. The transcriptional control by the PPAR/RXR heterodimer also requires interaction with coregulator complexes [44]. Thus, selective action of PPARs in vivo results from the interplay at a time point of each of the cofactors available. The RXRs are able to influence the transcription of a wide variety of genes, because they can activate gene transcription by binding to specific sites on DNA as homodimers and/or as the heterodimers with other related nuclear receptors including the PPARs, vitamin D receptor, and thyroid hormone receptors [45-47]. The temporal and spatial patterns of expression of PPARs and RXRs isoforms in the developing placenta have been elucidated [48]. In the human placenta, PPAR[alpha], PPAR[beta], and PPAR[gamma] are observed, while RXR[beta] is not detected. Immunocytochemistry staining results also determine the presence of PPAR[alpha], PPAR[beta], PPAR[gamma], RXR[alpha], and RXR[gamma] to be specific to the trophoblast layer of the human chorionic villi [49]. The presence of PPAR and RXR isoforms in placenta suggests that PPAR and RXR isoforms are potential regulators of placental lipid transfer and homeostasis. The PPARs/RXRs heterodimers may play a key regulatory role in placental development. It has been suggested that the PPARs/RXRs heterodimers may also function in the modulation of trophoblast invasion. There was no significant difference in PPARs or RXRs protein expression in both amnion and choriodecidua, which have been identified in gestational tissues [50-52].

4. Functional Interplay for the Transrepression of PPARs

The NAD(+)-dependent histone deacetylase Sir2 regulates life-span in various species [53]. Mammalian homologs of Sir2 are called Sirtuins (SIRT1-SIRT7) [54]. PPAR[alpha] and SIRT1 coordinately suppress genes involved in mitochondrial function [55] (Figure 3). Calorie restriction extends lifespan in organisms ranging from yeast to mammals. Upon food withdrawal, SIRT1 protein binds to and represses genes controlled by the fat regulator PPAR[gamma], including genes mediating fat storage. SIRT1 represses PPAR[gamma] by docking with its cofactors nuclear receptor corepressor and silencing mediator of retinoid and thyroid hormone receptors [56, 57]. The repression of PPAR[gamma] transactivation by SIRT1 inhibits lipid accumulation in adipocytes. SIRT1 also regulates angiogenesis signaling [58], which is expressed in the vasculature during blood vessel growth. Loss of SIRT1 function blocks sprouting angiogenesis and branching morphogenesis of endothelial cells with consequent downregulation of genes involved in blood vessel development and vascular remodeling. Human SIRT1 and SIRT2 are localized in the syncytiotrophoblast layer and the cytotrophoblasts of the placenta, amnion epithelium, trophoblast layer of the chorion, and decidual cells [59]. Resveratrol decreases proinflammatory TNF, IL6, and IL8 gene expression and resultant prostaglandin release from the gestational tissues [59]. SIRT1 also modulates gene expression in target tissues by regulating transcriptional coregulators or by directly interacting with transcription factors. SIRT1 overexpression prevents cytokine-mediated cytotoxicity, nitric oxide (NO) production, and inducible NO synthase expression. PPARs and SIRT1 may play a pivotal role in regulating pregnancy and parturition [59].

Many of the anti-inflammatory effects of PPAR[gamma] are caused by antagonizing the activities of the transcription factors including nuclear factor-kappa B (NF-[kappa]B) (Figure 3). EPA inhibited the NF-[kappa]B pathway in myotubes in a PPAR[gamma]-dependent manner. In one way for the inhibition, PPARs and these transcription factors bind each other via protein-protein interactions and prevent binding to their response elements. The ligand-activated PPARs have been shown to interfere with DNA binding of both AP-1 and NF-[kappa]B activity [60]. Furthermore, the mitogen-activated protein kinase (MAPK) pathway is also regulated by PPARs at different levels [61]. In addition, activation of PPAR[gamma] reduces c-Jun N-terminal kinase (JNK) and p38 MAPK activation, leading to downregulation of proinflammatory gene expression [62]. The transcription factors NF[kappa]B, CCAAT/enhancer-binding protein (CEBP), and AP-1 are important transcription factor families that are involved in immune and inflammatory functions as well as in cell growth and differentiation. Human placenta is rich in diverse bioactive molecules, whose extract induces interleukin mRNA and protein expressions in a dose-dependent manner. For example, the IL8 promoter contains binding sites for the NF[kappa]B, AP-1, and CEBP. The IL-8 expression is inhibited by an inhibitor of JNK [63, 64].

Interestingly, the transcriptional expression levels of fatty acid binding proteins are upregulated in males and downregulated in females [65]. A similar trend between sexes occurs for PPARs and CEBPs, which may be the upstream regulatory elements [65]. Estrogen-related receptors have been identified as PPAR coactivators, which upregulate the expression of PPAR[alpha] and PPAR[alpha]-regulated genes. Estrogen has not been reported to be a PPAR ligand, but interactions between PPARs and ER proteins and their response elements have been described [66]. These interactions might be due to estrogen induced production of PPAR activating metabolites. Studies have found that 17beta-estradiol upregulates the expression of PPAR[alpha] in skeletal muscle of rats [67].

A direct relationship between the PPARs activation and the inhibition of STAT5 mediated transcription has been reported [68, 69]. The PPARs do not block STAT5 tyrosine phosphorylation or do not inhibit DNA-binding activity but inhibit the transcriptional activity of STAT5. Conversely, activated STAT5 is able to inhibit PPAR-regulated gene transcription. In other words, STAT5-activating hormones and cytokines may modulate the responsiveness of PPARs to the chemical ligands. The cross-inhibitionbetween PPAR and STAT5 proceeds in a synchronized and bidirectional manner (Figure 3). Exposure to environmental chemical activators of PPARs may thus lead to alteration of hormone induced STAT5-regulated gene expression in tissues such as placenta, where both transcription factors are expressed.

5. Perspective

PPARs are lipid-activated transcription factors that have emerged as key regulators of both lipid metabolism and inflammation, and they exert positive and negative controls over the expression of a range of genes. However, the range of transcription factors affected and the molecular mechanism involved maybe different for each PPAR isoforms and cell types. Furthermore, peroxisome proliferators induce numerous alterations in lipid metabolism. A comparative approach to bring together physiological and nutritional roles of PPARs across species appears critical. It is now clear that PPARs are important in the control of placental development. PPARs may play a key role in linking lipid metabolism and reproduction systems. In addition, the PPAR[gamma]/RXR[alpha] signaling is important in human cytotrophoblast and cell fusions. A disturbed PPAR[gamma]/RXR[alpha] pathway could contribute to pathological human pregnancies. SIRT1 expression is downregulated by proinflammatory cytokines. Possessing anti-inflammatory action in human gestational tissues, the SIRT1 expression is downregulated by proinflammatory cytokines. The natural polyphenol resveratrol inhibits cytokine and prostaglandin release via the SIRT1 activation. Both mRNA and protein levels of SIRT1 are shown to decrease in placenta and fetal membranes after labor onset, which may contribute to uterine contractions associated with labor. It would be of interest to investigate the impact of different types of fatty acid, integrated into food, on ovulation capacity and fetal development. Further study of PPARs, RXRs, and SIRTs functions in placenta may indicate pathways that are common to critical processes, providing additional focus for research in important human placental diseases. In parallel, defining more specific mode of action by identifying the endogenous coactivators and modulators of these transcription factors in animal models will help to build more efficient therapeutic strategy for the diseases. Future studies using functional genomic approaches will be required to more clearly establish the complicated mechanisms by which PPARs exert their actions. Additional insight is also needed into endogenous PPAR and RXR ligands, how these molecules are formed, and how they are delivered to the nucleus in placenta. Furthermore, additional experiments are required to increase the knowledge of the way in which lipid metabolism influences reproductive functions.


AP-1:          Activator protein-1
CEBP:          CCAAT/enhancer-binding protein
COX:           Cyclooxygenase
JNK:           c-Jun N-terminal kinase
MAPK:          Mitogen activated protein kinase
NAD(+):        Nicotinamide adenine dinucleotide
NF-[kappa]B:   Nuclear factor-kappa B
NO:            Nitric oxide
PPAR:          Peroxisome proliferator-activated receptor
PPRE:          PPAR response element
RA:            Retinoic acid
RE:            Response element
RXR:           Retinoid X receptor
SIRT1:         Silent mating type information regulation 2 homolog 1
STAT:          Signal transducers and activators of transcription.

Conflict of Interests

The authors declare that they have no conflict of interests.


This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology in Japan. In addition, this work was supported in part by the grant from SHIN-EI Pharmaceutical Co., Ltd.


[1] M. Vacca, C. Degirolamo, R. Mariani-Costantini, G. Palasciano, and A. Moschetta, "Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome," Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 3, no. 5, pp. 562-587, 2011.

[2] I. G. Schulman, "Nuclear receptors as drug targets for metabolic disease," Advanced Drug Delivery Reviews, vol. 62, no. 13, pp. 1307-1315, 2010.

[3] W. Wahli and L. Michalik, "PPARs at the crossroads of lipid signaling and inflammation," Trends in Endocrinology & Metabolism, vol. 23, no. 7, pp. 351-363, 2012.

[4] J. Becker, C. Delayre-Orthez, N. Frossard, and F. Pons, "Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?" Fundamental and Clinical Pharmacology, vol. 20, no. 5, pp. 429-447, 2006.

[5] C. Giaginis, A. Tsantili-Kakoulidou, and S. Theocharis, "Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism," Fundamental and Clinical Pharmacology, vol. 21, no. 3, pp. 231-244, 2007.

[6] L. Nagy, A. Szanto, I. Szatmari, and L. Szeles, "Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response," Physiological Reviews, vol. 92, no. 2, pp. 739-789, 2012.

[7] M. C. Kruger, M. Coetzee, M. Haag, and H. Weiler, "Long-chain polyunsaturated fatty acids: selected mechanisms of action on bone," Progress in Lipid Research, vol. 49, no. 4, pp. 438-449, 2010.

[8] N. Martinez, M. Kurtz, E. Capobianco, R. Higa, V White, and A. Jawerbaum, "PPAR[alpha] agonists regulate lipid metabolism and nitric oxide production and prevent placental overgrowth in term placentas from diabetic rats," Journal of Molecular Endocrinology, vol. 47, no. 1, pp. 1-12, 2011.

[9] T. Shalom-Barak, J. M. Nicholas, Y. Wang et al., "Peroxisome proliferator-activated receptor y controls Muc1 transcription in trophoblasts," Molecular and Cellular Biology, vol. 24, no. 24, pp. 10661-10669, 2004.

[10] M. Puttabyatappa, C. A. VandeVoort, and C. L. Chaffin, "hCG-induced down-regulation of PPAR[gamma] and liver X receptors promotes periovulatory progesterone synthesis by macaque granulosa cells," Endocrinology, vol. 151, no. 12, pp. 5865-5872, 2010.

[11] M. P. Kowalewski, M. T. Dyson, P. R. Manna, and D. M. Stocco, "Involvement of peroxisome proliferator-activated receptor in gonadal steroidogenesis and steroidogenic acute regulatory protein expression," Reproduction, Fertility and Development, vol. 21, no. 7, pp. 909-922, 2009.

[12] H. Zhang, X. Xu, L. Chen et al., "Molecular determinants of magnolol targeting both RXR[alpha] and PPAR[gamma]," PLoS One, vol. 6, no. 11, article e28253, 2011.

[13] O. Wendling, P. Chambon, and M. Mark, "Retinoid X receptors are essential for early mouse development Land placentogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 2, pp. 547-551, 1999.

[14] Y. Barak, M. C. Nelson, E. S. Ong et al., "PPAR[gamma] is required for placental, cardiac, and adipose tissue development," Molecular Cell, vol. 4, no. 4, pp. 585-595, 1999.

[15] W. T. Schaiff, F. F. Knapp Jr., Y. Barak, T. Biron-Shental, D. M. Nelson, and Y. Sadovsky, "Ligand-activated peroxisome proliferator activated receptor [gamma] alters placental morphology and placental fatty acid uptake in mice," Endocrinology, vol. 148, no. 8, pp. 3625-3634, 2007.

[16] K. G. Lambe and J. D. Tugwood, "A human peroxisome-proliferator-activated receptor-[gamma] is activated by inducers of adipogenesis, including thiazalidinedione drugs," European Journal of Biochemistry, vol. 239, no. 1, pp. 1-7, 1996.

[17] R. L. Schild, C. M. Sonnenberg-Hirche, W. T. Schaiff, I. Bildirici, D. M. Nelson, and Y. Sadovsky, "The kinase p38 regulates peroxisome proliferator activated receptor-[gamma] in human trophoblasts," Placenta, vol. 27, no. 2-3, pp. 191-199, 2006.

[18] S. A. Degrelle, P. Murthi, D. Evain-Brion, T. Fournier, and I. Hue, "Expression and localization of DLX3, PPARG and SP1 in bovine trophoblast during binucleated cell differentiation," Placenta, vol. 32, no. 11, pp. 917-920, 2011.

[19] M. Ruebner, M. Langbein, P. L. Strissel et al., "Regulation of the human endogenous retroviral Syncytin-1 and cell-cell fusion by the nuclear hormone receptors PPAR[gamma]/RXR[alpha] in placentogenesis," Journal of Cellular Biochemistry, vol. 113, no. 7, pp. 2383-2396, 2012.

[20] R. Ringseis and K. Eder, "Influence of pharmacological PPAR[alpha] activators on carnitine homeostasis in proliferating and non-proliferating species," Pharmacological Research, vol. 60, no. 3, pp. 179-184, 2009.

[21] K. D. Wagner and N. Wagner, "Peroxisome proliferator-activated receptor beta/delta (PPAR[beta]/[delta]) acts as regulator of metabolism linked to multiple cellular functions," Pharmacology and Therapeutics, vol. 125, no. 3, pp. 423-435, 2010.

[22] D. Cipolletta, M. Feuerer, A. Li et al., "PPAR-[gamma] is a major driver of the accumulation and phenotype of adipose tissue Treg cells," Nature, vol. 486, no. 7404, pp. 549-553, 2012.

[23] C. Huin, L. Corriveau, A. Bianchi et al., "Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract," Journal of Histochemistry and Cytochemistry, vol. 48, no. 5, pp. 603-611, 2000.

[24] C. M. Komar and T. E. Curry, "Localization and expression of messenger RNAs for the peroxisome proliferator-activated receptors in ovarian tissue from naturally cycling and pseudo-pregnant rats," Biology of Reproduction, vol. 66, no. 5, pp. 1531-1539, 2002.

[25] L. Fedele, E. Somigliana, G. Frontino, L. Benaglia, and P. Vigano, "New drugs in development for the treatment of endometriosis," Expert Opinion on Investigational Drugs, vol. 17, no. 8, pp. 1187-1202, 2008.

[26] Y. Gui, Z. Cai, J. V. Silha, and L. J. Murphy, "Variations in parametrial white adipose tissue mass during the mouse estrous cycle: relationship with the expression of peroxisome proliferator-activated receptor-y and retinoic acid receptor-a," Canadian Journal of Physiology and Pharmacology, vol. 84, no. 8-9, pp. 887-892, 2006.

[27] V. Benz, U. Kintscher, and A. Foryst-Ludwig, "Sex-specific differences in type 2 diabetes mellitus and dyslipidemia therapy: PPAR agonists," Handbook of Experimental Pharmacology, vol. 214, pp. 387-410, 2012.

[28] T. Waku, T. Shiraki, T. Oyama, and K. Morikawa, "Atomic structure of mutant PPAR[gamma] LBD complexed with 15d-PGJ2: novel modulation mechanism of PPAR[gamma]/RXR[alpha] function by covalently bound ligands," FEBS Letters, vol. 583, no. 2, pp. 320-324, 2009.

[29] S. Yu and J. K. Reddy, "Transcription coactivators for peroxisome proliferator-activated receptors," Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 936-951, 2007

[30] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, "15-deoxy-[DELTA]12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR[gamma]," Cell, vol. 83, no. 5, pp. 803-812, 1995.

[31] Z. Yu, C. Schneider, W. E. Boeglin, and A. R. Brash, "Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPAR[alpha]," Lipids, vol. 42, no. 6, pp. 491-497, 2007.

[32] A. Ibabe, A. Herrero, and M. P. Cajaraville, "Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR[alpha]- and PPAR[gamma]-specific ligands and by 17[beta]-estradiol in isolated zebrafish hepatocytes," Toxicology in Vitro, vol. 19, no. 6, pp. 725-735, 2005.

[33] I. Kouroumichakis, N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos, and D. P. Mikhailidis, "Fibrates: therapeutic potential for diabetic nephropathy?" European Journal of Internal Medicine, vol. 23, no. 4, pp. 309-316, 2012.

[34] S. N. Friedland, A. Leong, K. B. Filion et al., "The cardiovascular effects of peroxisome proliferator-activated receptor agonists," American Journal of Medicine, vol. 125, no. 2, pp. 126-133, 2012.

[35] N. Saraf, P. K. Sharma, S. C. Mondal, V. K. Garg, and A. K. Singh, "Role of PPARg2 transcription factor in thiazolidinedioneinduced insulin sensitization," Journal of Pharmacy and Pharmacology, vol. 64, no. 2, pp. 161-171, 2012.

[36] K. Subbaramaiah, D. T. Lin, J. C. Hart, and A. J. Dannenberg, "Peroxisome proliferator-activated receptor [gamma] ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300," Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440-12448, 2001.

[37] H. Matsumoto, W. Ma, W. Smalley, J. Trzaskos, R. M. Breyer, and S. K. Dey, "Diversification of cyclooxygenase-2-derived prostaglandins in ovulation and implantation," Biology of Reproduction, vol. 64, no. 5, pp. 1557-1565, 2001.

[38] K. H. Ruan and J. M. Dogne, "Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs," Current Pharmaceutical Design, vol. 12, no. 8, pp. 925-941, 2006.

[39] P. Froment, F. Gizard, D. Defever, B. Staels, J. Dupont, and P. Monget, "Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition," Journal of Endocrinology, vol. 189, no. 2, pp. 199-209, 2006.

[40] M. Mendez and M. C. LaPointe, "PPAR[gamma] inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes," Hypertension, vol. 42, no. 4, pp. 844-850, 2003.

[41] T. Fournier, L. Pavan, A. Tarrade et al., "The role of PPAR-[gamma]/RXR- [alpha] heterodimers in the regulation of human trophoblast invasion," Annals of the New York Academy of Sciences, vol. 973, pp. 26-30, 2002.

[42] A. Tarrade, K. Schoonjans, J. Guibourdenche et al., "PPAR[gamma]/RXR[alpha] heterodimers are involved in human CG[beta] synthesis and human trophoblast differentiation," Endocrinology, vol. 142, no. 10, pp. 4504-4514, 2001.

[43] A. Tarrade, C. Rochette-Egly, J. Guibourdenche, and D. EvainBrion, "The expression of nuclear retinoid receptors in human implantation," Placenta, vol. 21, no. 7, pp. 703-710, 2000.

[44] L. Michalik, J. Auwerx, J. P. Berger et al., "International union of pharmacology. LXI. Peroxisome proliferator-activated receptors," Pharmacological Reviews, vol. 58, no. 4, pp. 726-741, 2006.

[45] G. Wolf, "Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor?" Nutrition Reviews, vol. 64, no. 12, pp. 532-538, 2006.

[46] P. Nezbedova and J. Brtko, "1[alpha],25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action," Endocrine Regulations, vol. 38, no. 1, pp. 29-38, 2004.

[47] S. D. Clarke, P. Thuillier, R. A. Baillie, and X. Sha, "Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors," American Journal of Clinical Nutrition, vol. 70, no. 4, pp. 566-571, 1999.

[48] Q. Wang, H. Fujii, and G. T. Knipp, "Expression of PPAR and RXR isoforms in the developing rat and human term placentas," Placenta, vol. 23, no. 8-9, pp. 661-671, 2002.

[49] K. Handschuh, J. Guibourdenche, M. Cocquebert et al., "Expression and regulation by PPAR[gamma] of hCG [alpha]- and [beta]-subunits: comparison between villous and invasive extravillous trophoblastic Cells," Placenta, vol. 30, no. 12, pp. 1016-1022, 2009.

[50] S. J. Holdsworth-Carson, M. Permezel, G. E. Rice, and M. Lappas, "Preterm and infection-driven preterm labor: the role of peroxisome proliferator-activated receptors and retinoid X receptor," Reproduction, vol. 137, no. 6, pp. 1007-1015, 2009.

[51] S. J. Holdsworth-Carson, M. Permezel, C. Riley, G. E. Rice, and M. Lappas, "Peroxisome Proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated Changes," Placenta, vol. 30, no. 2, pp. 176-186, 2009.

[52] V. Borel, D. Gallot, G. Marceau, V. Sapin, and L. Blanchon, "Placental implications of peroxisome proliferator-activated receptors in gestation and parturition," PPAR Research, vol. 2008, Article ID 758562, 9 pages, 2008.

[53] S. J. Lin, E. Ford, M. Haigis, G. Liszt, and L. Guarente, "Calorie restriction extends yeast life span by lowering the level of NADH," Genes and Development, vol. 18, no. 1, pp. 12-16, 2004.

[54] M. Potente, L. Ghaeni, D. Baldessari et al., "SIRT1 controls endothelial angiogenic functions during vascular growth," Genes and Development, vol. 21, no. 20, pp. 2644-2658, 2007

[55] S. Oka, R. Alcendor, P. Zhai et al., "PPAR[alpha]-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway," Cell Metabolism, vol. 14, no. 5, pp. 598-611, 2011.

[56] A. Legutko, T. Marichal, L. Fievez et al., "Sirtuin 1 promotes Th2 responses and airway allergy by repressing peroxisome proliferator-activated receptor-y activity in dendritic cells," The Journal of Immunology, vol. 187, no. 9, pp. 4517-4529, 2011.

[57] F. Picard, M. Kurtev, N. Chung et al., "Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-[gamma]," Nature, vol. 429, no. 6993, pp. 771-776, 2004.

[58] H. Miyashita, T. Watanabe, H. Hayashi et al., "Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1," PLoS One, vol. 7, no. 10, article e46459, 2012.

[59] M. Lappas, A. Mitton, R. Lim, G. Barker, C. Riley, and M. Permezel, "SIRT1 is a novel regulator of key pathways of human labor," Biology of Reproduction, vol. 84, no. 1, pp. 167-178, 2011.

[60] J. K. Kim, S. Mun, M. S. Kim, M. B. Kim, B. K. Sa, and J. K. Hwang, "5, 7-Dimethoxyflavone, an activator of PPAR[alpha]/[gamma], inhibits UVB-induced MMP expression in human skin fibroblast cells," Experimental Dermatology, vol. 21, no. 3, pp. 211-216, 2012.

[61] E. Papageorgiou, N. Pitulis, P. Msaouel, P. Lembessis, and M. Koutsilieris, "The non-genomic crosstalk between PPAR-[gamma] ligands and ERK1/2 in cancer cell lines," Expert Opinion on Therapeutic Targets, vol. 11, no. 8, pp. 1071-1085, 2007

[62] T. Pang, J. Wang, J. Benicky, E. Sanchez-Lemus, and J. M. Saavedra, "Telmisartan directly ameliorates the neuronal inflammatory response to IL-1[beta] partly through the JNK/c-Jun and NADPH oxidase pathways," Journal of Neuroinflammation, vol. 9, no. 1, p. 102, 2012.

[63] N. Patel, C. S. Gonsalves, P. Malik, and V. K. Kalra, "Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1[alpha]," Blood, vol. 112, no. 3, pp. 856-865, 2008.

[64] D. Maldonado-Perez, P. Brown, K. Morgan, R. P. Millar, E. A. Thompson, and H. N. Jabbour, "Prokineticin 1 modulates IL-8 expression via the calcineurin/NFAT signaling pathway," Biochimica et Biophysica Acta, vol. 1793, no. 7, pp. 1315-1324, 2009.

[65] W. Zhang, Y. Zhang, H. Zhang, J. Wang, R. Cui, and J. Dai, "Sex differences in transcriptional expression of FABPs in zebrafish liver after chronic perfluorononanoic acid exposure," Environmental Science & Technology, vol. 46, no. 9, pp. 51755182, 2012.

[66] J. M. Keller, P. Collet, A. Bianchi et al., "Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease," International Journal of Developmental Biology, vol. 44, no. 5, pp. 429-442, 2000.

[67] S. E. Campbell, K. A. Mehan, R. J. Tunstall, M. A. Febbraio, and D. Cameron-Smith, "17[beta]-Estradiol upregulates the expression of peroxisome proliferator-activated receptor [alpha] and lipid oxidative genes in skeletal muscle," Journal of Molecular Endocrinology, vol. 31, no. 1, pp. 37-45, 2003.

[68] U. A. White and J. M. Stephens, "Transcriptional factors that promote formation of white adipose tissue," Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 10-14, 2010.

[69] H. S. Jung, Y. J. Lee, Y. H. Kim, S. Paik, J. W. Kim, and J. W. Lee, "Peroxisome proliferator-activated receptor gamma/signal transducers and activators of transcription 5A pathway plays a key factor in adipogenesis of human bone marrow-derived stromal cells and 3T3-L1 preadipocytes," Stem Cells and Development, vol. 21, no. 3, pp. 465-475, 2012.

Satoru Matsuda, Mayumi Kobayashi, and Yasuko Kitagishi

Department of Environmental Health Science, Nara Women's University, Kita-Uoya

Nishimachi, Nara 630-8506, Japan

Correspondence should be addressed to Satoru Matsuda;

Received 30 November 2012; Revised 16 January 2013; Accepted 16 January 2013

Academic Editor: Udo Jeschke
COPYRIGHT 2013 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Matsuda, Satoru; Kobayashi, Mayumi; Kitagishi, Yasuko
Publication:PPAR Research
Article Type:Report
Date:Jan 1, 2013
Previous Article:Structural features and transcriptional activity of chicken PPARS ([alpha], [beta], and [gamma]).
Next Article:The PPAR[alpha]/[gamma] agonist, tesaglitazar, improves insulin mediated switching of tissue glucose and free fatty acid utilization in vivo in the...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters